Mayurkumar Bhakta, MD
Interventional Cardiology · Scottsdale, AZNPI 1831176346
Payments from drug & device makers
Across 474 payments — averaging $172.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$36K
- Abbott$30K
- Medtronic$8K
- Boston Scientific$5K
- Abiomed$637
- Novartis$570
- plus $2K from 25 others
What the payments were for
- Consulting fees$1,8003%
- Speaking & faculty fees$34,70055%
- Travel & lodging$9,15715%
- Food & beverage$17,22527%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 101 | $35,787 |
| Abbott | 139 | $29,545 |
| Medtronic(2 entities) | 38 | $8,144 |
| Boston Scientific | 48 | $4,829 |
| Abiomed | 17 | $637 |
| Novartis | 63 | $570 |
| Bayer | 2 | $286 |
| Teleflex LLC | 2 | $195 |
| Chiesi USA, Inc. | 9 | $174 |
| Shockwave Medical, Inc | 1 | $173 |
| Amgen | 10 | $166 |
| Itamar Medical Inc | 1 | $147 |
| ZOLL Respicardia, Inc. | 1 | $139 |
| Johnson & Johnson | 9 | $133 |
| Atricure, Inc. | 2 | $111 |
| Philips North America LLC | 1 | $110 |
| Merck | 5 | $86 |
| Impulse Dynamics (USA) Inc. | 1 | $61 |
| E.r. Squibb & Sons, L.L.C. | 4 | $52 |
| Cardiva Medical, Inc. | 3 | $48 |
| AstraZeneca | 3 | $46 |
| Boehringer Ingelheim | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Actelion Pharmaceuticals US, Inc. | 2 | $27 |
| Pfizer | 2 | $26 |
| Avinger Inc. | 1 | $24 |
| Cardiovascular Systems Inc. | 1 | $18 |
| Biosense Webster, Inc. | 1 | $15 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| W. L. Gore & Associates, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$33,548
- Resolute$5,828
- Xience V coronary stent system$2,700
- OPTIS$2,088
- GENERAL - THERAPIES$1,800
- Watchman$1,272
- CARDIOMEMS$1,061
- Micra$716
- Quadra Assura CRT Defibrillator$472
- 3F$432
- WATCHMAN Access System$423
- AVEIR$301
- Optis Coronary Imaging System$291
- Kerendia$286
- Assurity Pacemaker$277
- DRAGONFLY OPSTAR$253
- FlexAbility Ablation Catheter$181
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$173
- MANTA$162
- PORTICO$161
How this compares
$81,658 in reported general payments places this provider in the 80th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 257 | $260,338 |
| EntrestoSacubitril/Valsartan | 112 | $111,446 |
| Repatha SureclickEvolocumab | 105 | $83,308 |
| XareltoRivaroxaban | 67 | $76,728 |
| BrilintaTicagrelor | 62 | $47,153 |
| FarxigaDapagliflozin Propanediol | 27 | $18,847 |
| CorlanorIvabradine Hcl | 13 | $14,784 |
| Praluent PenAlirocumab | 12 | $9,608 |
| JardianceEmpagliflozin | 11 | $6,361 |
| Metoprolol Succinate | 305 | $3,708 |
| Flecainide Acetate | 50 | $3,357 |
| Rosuvastatin Calcium | 218 | $2,889 |
| Atorvastatin Calcium | 307 | $2,692 |
| ClopidogrelClopidogrel Bisulfate | 243 | $2,325 |
| Valsartan | 67 | $2,269 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $26 | $260,338257 claims |
| NovartisEntresto | $570 | $111,446112 claims |
| Johnson & JohnsonXarelto | $133 | $76,72867 claims |
| AstraZenecaBrilinta, Farxiga | $46 | $66,00089 claims |
| AmgenCorlanor | $166 | $14,78413 claims |
| Boehringer IngelheimJardiance | $35 | $6,36111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Scottsdale
- Taral PatelScottsdale$377K
- Andrew CluckeyScottsdale$116K
- Rebecca ChesterScottsdale$113K
- Nassim HaddadScottsdale$53K
- Kwan LeeScottsdale$53K
- Paul SorajjaPhoenix$8.8M
- Thomas WaggonerTucson$4.1M
- Hursh NaikAvondale$2.2M
- Nabil DibGilbert$2.2M
- Timothy ByrnePhoenix$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.